Category

In the News

Sleep is associated with tau pathology in early Alzheimer’s disease

By | Community Events, In the News | No Comments

Colleagues at Washington University School of Medicine published novel findings on the correlation between tau tangles, a hallmark of Alzheimer’s disease pathology, and sleep quality in people who were cognitively normal or who had mild cognitive impairment. On ALZFORUM, UCI MIND faculty member, Dr. Bryce Mander commented, “This is an important paper because it shows for the first time how tau is related to sleep deficits. That’s going to be important in advancing our understanding of how Alzheimer’s disease pathology affects sleep.” Dr. Mander, Assistant Professor of Psychiatry & Human Behavior at UCI, has published several important findings on the link between…

Read More

Dr. Ira Lott, Director of UCI MIND Down Syndrome Program, featured in OC Business Journal

By | Carousel Slider, In the News | No Comments

Dr. Ira Lott, Director of the UCI MIND Down Syndrome Program, discussed the connection between Down syndrome and Alzheimer’s disease with the Orange County Business Journal this week.  Dr. Lott and his team conduct critical research studies with volunteer participants to improve understanding of brain aging and dementia in Down syndrome. Click here to read the article > To learn more about studies in Down syndrome and Alzheimer’s disease, click here >

Read More

Critical need for diversity in Alzheimer’s disease research

By | Commentary, In the News | No Comments

Contributed by Joshua Grill, PhD, Director of UCI MIND In a new study, colleagues at the Alzheimer’s Disease Research Center at Washington University have found that levels of the cerebrospinal fluid protein tau, one of the hallmark pathologies in Alzheimer’s disease (AD), is lower in African Americans compared to Whites. This was true both for older participants who did and did not have memory problems. The study is not the first to find such differences between African Americans and Caucasians and it has important implications to a number of important areas of AD research. First, there is a growing movement…

Read More

Novel genetics research opens door to potential new therapies for dementia

By | Carousel Slider, In the News | No Comments

UCI MIND faculty member, Dr. Vivek Swarup, and colleagues at UCLA, Takeda Pharmaceutical Co. Ltd. in Japan, Emory University School of Medicine, Harvard Medical School, and the Perelman School of Medicine at the University of Pennsylvania, published novel findings yesterday in Nature Medicine on two major groups of genes associated  with Alzheimer’s disease and frontotemporal dementia and unraveled a novel microRNA, miR-203, as a master regulator of neuronal death. In human cell cultures containing AD-associated mutations, the researchers showed that certain experimental drugs altered the loss of brain cells associated with neurodegenerative disease. Dr. Swarup says, “I’m hopeful these important findings will bring us one step closer to effective new treatments…

Read More

Fall 2018 Newsletter – In this issue of MIND Matters

By | In the News | No Comments

Fall 2018 Newsletter – In this issue of MIND Matters: – Grand Opening of UCI Sleep Center led by Dr. Ruth Benca – Wine for the MIND hosted by Bob & Virginia Naeve – Meet the REMIND Co-Chairs – Study Partners in Alzheimer’s Research: Gwen Ritchie – Philanthropist Highlight: Greg & Cindy Lai – Donations, Sept 2017-2018 —– Click to read the Fall 2018 Newsletter – MIND Matters

Read More

Dr. Blurton-Jones awarded grant to identify potential treatments for Alzheimer’s disease

By | Carousel Slider, In the News | No Comments

UCI MIND faculty member Dr. Mathew Blurton-Jones was awarded a $500,000 grant from Orange County Community Foundation to test 1200+ FDA-approved compounds for effectiveness in Alzheimer’s disease treatment. His lab seeks to find the top 20 genes and drugs that safely prevent brain damage caused by microglia, which are critical immune cells in the brain that ‘prune’ unnecessary neuronal connections, or synapses. In the brains of people with Alzheimer’s disease, damage can be caused by microglia ‘overpruning’ synapses, leading to loss of necessary connections. UCI News reports that Dr. Blurton-Jones and his team are “grateful to be the recipients of this…

Read More

UCI MIND selected as Center of Excellence to conduct clinical trials in Down Syndrome and Alzheimer’s disease

By | Carousel Slider, In the News | No Comments

UCI MIND faculty member, Dr. Ira Lott, is one of the world’s leading experts in unraveling the link between Down syndrome and Alzheimer’s disease (Learn more in the Winter 2016 issue of MIND Matters). His team has been selected as a Center of Excellence for the new Down Syndrome Clinical Trial Network (DS-CTN) launched by LuMIND, a Down syndrome research foundation. As part of this important network, Dr. Lott and his team will receive funding to conduct clinical trials of promising therapies for participants with Down syndrome, at risk for Alzheimer’s disease. To learn more about the initiative and the…

Read More

Sandra Day O’Connor announces dementia diagnosis

By | In the News | No Comments

In a letter released on Tuesday, October 23, retired supreme court justice Sandra Day O’Connor announced a diagnosis of probable Alzheimer’s dementia, and that she will begin stepping down from public life. O’Connor, the first woman to serve on the Supreme Court, was a devoted caregiver to her husband John after his Alzheimer’s diagnosis in 2005. NPR reports the reaction of Chief Justice John Roberts: “I was saddened to learn that Justice Sandra Day O’Connor, like many Americans, faces the challenge of dementia. But I was not at all surprised that she used the occasion of sharing that fact to think…

Read More

Dr. Joshua Grill discusses A4 Study results in Alzforum

By | Carousel Slider, Commentary, In the News | No Comments

This week Alzforum posted coverage from the Alzheimer’s Association International Conference, including UCI MIND Director Dr. Joshua Grill’s presentation of data from The A4 Study (Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease Study). In The A4 Study, a secondary prevention trial of late-onset Alzheimer’s disease, people with elevated amyloid had higher levels of memory complaints than those without elevated amyloid. To read the full article, click here > 

Read More